RICT 2012 - Interfacing Chemical Biology and Drug Discovery
Confirmed speakers
 DNA Methylation Inhibitors In Cancer: Recent and Future Approaches
Dr Paola ARIMONDO
(CNRS - PIERRE FABRE, Toulouse, France)

Read more
 Sometimes You Just Have to Break the Rules ..
Dr Yves P. AUBERSON
(NOVARTIS INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

Read more
 A Yeast-based Model for Prion Disease Allowed Isolation of Specific and Competitive Inhibitors of a New Protein Chaperone Activity Borne by the Ribosome that are Active Against Other Amyloid-based Diseases
Prof. Marc BLONDEL
(INSERM, Brest, France)

Read more
 JNJ-42153605: A Novel Positive Allosteric Modulator of mGluR2 for the Treatment of CNS Disorders
Dr Jose CID
(JANSSEN RESEARCH AND DEVELOPMENT, Toledo, Spain)

Read more
 Accelerating Drug Discovery through High Throughput Medicinal Chemistry - Alternative Lead Finding & Optimisation Approaches Including Representative Project Examples
Dr Werngard CZECHTIZKY
(SANOFI, Frankfurt am Main, Germany)

Read more
 Squalenoyl Nanomedicines as Potential Therapeutics
Dr Didier DESMAËLE
(UNIVERSITÉ PARIS SUD, Châtenay-Malabry, France)

Read more
 Reduce to the Max – Probing Biology with Natural Product Fragments
Prof. Karl GADEMANN
(UNIVERSITY OF BASEL, Basel, Switzerland)

Read more
 Antagonists of the p53/hdm2 Protein-Protein Interaction - Path to the Clinic
Dr Carlos GARCIA-ECHEVERRIA
(SANOFI, Vitry sur Seine, France)

Read more
 Bicyclic Peptide Antagonists Isolated From Phage Display Libraries
Prof. Christian HEINIS
(ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland)

Read more
 Perspectives in Structure and Fragment Based Drug Discovery
Prof. Rod HUBBARD
(UNIVERSITY OF YORK / VERNALIS, York, United Kingdom)

Read more
 Structure and Function of Acid-Sensing Ion Channels
Dr Stephan KELLENBERGER
(UNIVERSITÉ DE LAUSANNE, Lausanne, Switzerland)

Read more
 Targeting Protein Interactions Mediated by Epigenetic Acetyl-lysine Reader Domains of the Bromodomain Family
Prof. Stefan KNAPP
(OXFORD UNIVERSITY, Oxford, United Kingdom)

Read more
 Protein-binding Prodrugs and Drug Conjugates in Oncology: From Design, Applications to Combination Therapy
Prof. Felix KRATZ
(TUMOR BIOLOGY CENTER, Freiburg, Germany)
 Pharmacophore-based Parallel in Silico Screening: An Interesting Concept for Efficient Activity Profiling in Drug Discovery
Prof. Thierry LANGER
(PRESTWICK CHEMICAL, Illkirch, France)

Read more
 Translating Structural-biology & Preclinical Activity of Nilotinib into Efficacy in Leukemia Patients
Dr Paul W. MANLEY
(NOVARTIS PHARMA, Basel, Switzerland)

Read more
 Two Chemical/Biological Approaches to Alzheimer's Disease: Prevention and Therapy
Charles Mentzer Prize Lecture
Dr Laurent MEIJER
(MANROS THERAPEUTICS, Roscoff, France)

Read more
 From ApoA1 Upregulation to BET Family Bromodomain Inhibition: Unlocking the Potential of an Epigenetic Target Class
Dr Olivier MIRGUET
(GLAXOSMITHKLINE, Les Ulis, France)

Read more
 Synthetic Carbohydrates in the Search for Tailor-made Antibacterial Vaccines: Shigellosis as a Challenge
Dr Laurence MULARD
(INSTITUT PASTEUR, Paris, France)

Read more
 Chemical space exploration via Natural Product-like compounds
Dr Jean-Yves ORTHOLAND
(EDELRIS, Lyon, France)

Read more
 Discovery of RG1678, a First in Class Glycine Reuptake Inhibitor for the Treatment of Schizophrenia
Dr Emmanuel PINARD
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

Read more
 A Look at Some Innovative Chemical Aspects in Medicinal Chemistry, about Heterocycles, Microwaves, Chemical Libraries, Boronics and Garlands
Paul Ehrlich Prize Lecture
Prof. Sylvain RAULT
(UNIVERSITÉ DE CAEN, Caen Cedex, France)

Read more
 Combined Use of Noncovalent Mass Spectrometry and Other Biophysical Techniques in Early-stage Drug Discovery
Dr Jean-Paul RENAUD
(NOVALIX, Illkirch, France)

Read more
 Sorafenib – A Signal Transduction Inhibitor for the Treatment of Liver Cancer
Dr Bernd RIEDL
(BAYER PHARMA, Wuppertal, Germany)

Read more
 Progress on Allosteric Modulation of mGluR5 and mGluR4: towards New Treatment Paradigms in Parkinson’s Disease
Dr Jean-Philippe ROCHER
(ADDEX THERAPEUTICS, Plan-les-Ouates, Switzerland)

Read more
 Potent Antibody Drug Conjugates for Cancer Therapy: From the Lab to a Clinically Approved Drug
Dr Peter SENTER
(SEATTLE GENETICS, Bothell, United States)

Read more
 SV2 Proteins Beyond Levetiracetam: The Discovery of the First SV2C Selective Ligands
Dr Anne VALADE
(UCB, Braine-l'Alleud, Belgium)

Read more
 Matched Triplicate Design Sets in the Optimisation of a New Series of Glucokinase Activators
Dr Mike WARING
(ASTRAZENECA, Macclesfield, United Kingdom)

Read more
<Previous page


Organised by

Major Sponsors

Media Partners